2018
DOI: 10.1016/j.ekir.2018.07.021
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study

Abstract: IntroductionThe Cure Glomerulonephropathy Network (CureGN) is a 66-center longitudinal observational study of patients with biopsy-confirmed minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (IgAN), including IgA vasculitis (IgAV). This study describes the clinical characteristics and treatment patterns in the IgA cohort, including comparisons between IgAN versus IgAV and adult versus pediatric patients.MethodsPatients with a diagnostic kidney biopsy within … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
31
0
4

Year Published

2020
2020
2022
2022

Publication Types

Select...
4
3
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 56 publications
(37 citation statements)
references
References 33 publications
2
31
0
4
Order By: Relevance
“…In contrast, HSPN patients showed a higher rate and signi cant higher level of proteinuria and signi cantly more endocapillary hypercellularity. Recently, the CureGN study, a large register study, investigated a subgroup of 285 pediatric IgAN and HSPN patients [1]. Consistent with our results, they found a higher age in pediatric IgAN compared to HSPN patients with the mean ages of both groups being very similar to our monocentric patient cohort.…”
Section: Discussionsupporting
confidence: 91%
“…In contrast, HSPN patients showed a higher rate and signi cant higher level of proteinuria and signi cantly more endocapillary hypercellularity. Recently, the CureGN study, a large register study, investigated a subgroup of 285 pediatric IgAN and HSPN patients [1]. Consistent with our results, they found a higher age in pediatric IgAN compared to HSPN patients with the mean ages of both groups being very similar to our monocentric patient cohort.…”
Section: Discussionsupporting
confidence: 91%
“…Treatment with CS might lessen the severity and duration of GI, joint, and cutaneous symptoms [ 28 , 30 ], but does not alter the disease course nor prevent renal involvement [ 27 , 31 , 32 ]. In the literature, around 19.8–73.2% patients required CS use [ 12 , 33 , 34 ], while 0–75.9% patients took DMARDs [ 12 , 34 ]. The variation in the reported administration rate of CS and DMARDs could relate to differences in disease severity and clinical characteristics in different studies.…”
Section: Discussionmentioning
confidence: 99%
“…ГКС снижают риск прогрессирования и необходимость в почечной заместительной терапии. Задачей представляется идентификация характеристик, которые могли бы предсказать лучшую терапевтическую тактику и ответ на лечение [17][18][19][20].…”
Section: Discussionunclassified
“…крупных центров [19][20][21][22][23][24][25][26]. АГ выявлена в 9 % случаев, снижения рСКФ в данной подгруппе не отмечалось.…”
Section: рисунок 4 игх окрашивание с ат к Vegf: умеренно выраженноеunclassified